WFDC2 and ovarian carcinoma: Tumor associated autoantibodies may improve on the performance of CA125 alone as we recently described for the human epididymis protein 4 (HE4) antigen–autoantibody complexes as complementing CA125 for detecting early-stage ovarian cancer [7].